Oct. 23, 2020, New York, NY - Patients with diabetic kidney disease can potentially be treated with a new investigational medication that may slow the progress of their illness without harmful side effects to their hearts, according to the results of a global clinical trial announced today.
'This is an exciting and
Related News
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin...
Public Technologies 2020-10-22Strataca Systems®, Ltd. To Present New Data Demonstrating Improved Kidney Function Associated with JuxtaFlow® Renal Negative Pressure Treatment in Animal Models With and Without Congestive Heart Failure
Strataca Systems®, Ltd. To Present New Data Demonstrating Improved Kidney Function Associated with JuxtaFlow® Renal Negative Pressure Treatment in Animal Models With and...
Pharmiweb 2020-10-23Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve...
PR Newswire 2020-10-22American Ninja Warrior and National Kidney Foundation Join Forces to Help Kidney Patients Find a Living Donor
October 22, 2020, New York, NY-American Ninja Warrior competitor Austin Gray joins forces with The National Kidney Foundation (NKF) to help kidney patients who need a...
Public Technologies 2020-10-22American Ninja Warrior and National Kidney Foundation Join Forces to Help Kidney Patients Find a ...
NEW YORK, Oct. 22, 2020 /PRNewswire/ -- American Ninja Warrior competitor Austin Gray joins forces with The National Kidney Foundation (NKF) to help kidney patients who...
The Philadelphia Tribune
2020-10-22
National Kidney Foundation Announces Atlanta Business Executive and Kidney Transplant Patient Anthony E. Tuggle as ...
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- The National Kidney Foundation (NKF) is pleased to announce the appointment of Anthony E. Tuggle as Chair of its National Board of...
Olean Times Herald
2020-10-20
Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3...
PR Newswire 2020-10-22Related News
Bayer’s FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes ...
The Marshall News Messenger
2020-10-23